The Immune Response Corporation Announces Publication of Data Suggesti

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    CARLSBAD, Calif.--(BUSINESS WIRE)--April 19, 2005--The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today a preclinical study demonstrating the potential for a gp120-deleted HIV-1 antigen (a component of REMUNE(R)) with a CpG oligonucleotide adjuvant to have a protective role when administered to Trimera mice prior to HIV infection challenge. The results of this study in mice were published by the FASEB Journal online (FASEB J. Apr 15, 2005, doi:10.1096/fj.04-3185fje) and can be viewed at http://www.fasebj.org/express/.
    "This publication tends to validate the animal model and the potential for an HIV-1 antigen as a preventive therapy. While this is very exciting research, it is too early to make comparisons to REMUNE(R) or IR103," said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. "The HIV-1 antigen used in this study is the same antigen contained in REMUNE(R) and IR103; and the CpG adjuvant in this study is very similar to the Amplivax(TM) adjuvant contained in IR103. We expect results at least equal to these if we repeat this study with our products. We are currently planning a study with the same components of IR103 using this model."

    About The Immune Response Corporation

    The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company's HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.
    The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax(TM), which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.
    Please visit The Immune Response Corporation at www.imnr.com

    This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

    REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation. Amplivax(TM) is a trademark of Hybridon, Inc.

--30--TJJ/la*

CONTACT: The Immune Response Corporation (Investor Contact) Michael K. Green, Chief Financial Officer, 760-431-7080 info@imnr.com or Sam Brown Inc. Corporate Communication (Media Contact) Laura Silver, 310-551-9940 silver@sambrown.com

KEYWORD: CALIFORNIA UNITED KINGDOM INTERNATIONAL CANADA EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MEDICAL PRODUCT SOURCE: The Immune Response Corporation

Copyright Business Wire 2005